Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.
Younger Indians have a 10 times higher rate of heart attack
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Medicines, including insulin, to be available in 40 lower-income countries
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Subscribe To Our Newsletter & Stay Updated